Camlipixant(Camlipixant) - 药物靶点：P2X3 receptor_在研适应症：不明原因的慢性咳嗽，难治性慢性咳嗽，咳嗽_专利_临床

概要

基本信息

药物类型

小分子化药

别名

AZ-13410937、AZ13410937、BLU 5937

+ [3]

靶点

P2X3 receptor

作用方式

拮抗剂

作用机制

P2X3 receptor拮抗剂(嘌呤P2X3受体拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

BELLUS Health, Inc.BELLUS Health Cough, Inc.

Neomed Institute

非在研机构-

权益机构

BELLUS Health, Inc.

GSK Plc

Neomed Institute

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H24F2N4O4

InChIKeySEHLMRJSQFAPCJ-HNNXBMFYSA-N

CAS号1621164-74-6

关联

15

项与 Camlipixant 相关的临床试验

NCT06497517

/ Completed临床1期

A Phase 1, Single Center, Single Dose, Open-Label, Randomized, 2-Way Crossover Study to Investigate the Food Effect on the Pharmacokinetics of Camlipixant in Healthy Male and Female Participants

This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female participants. Eligible participants will be randomized to pre-defined sequences. There will be a washout of minimum 7 days between each dose of treatment period.

开始日期2024-07-09

申办/合作机构

BELLUS Health, Inc.

CTR20240965

/ Recruiting临床3期

一项在难治性或不明原因慢性咳嗽成人受试者中进行BLU-5937开放性扩展治疗的III期、24周、随机、疗效和安全性研究

主要目的：评估BLU-5937与安慰剂相比在基线24小时咳嗽频率≥8次咳嗽/小时的RCC（包括不明原因的慢性咳嗽）成人患者中对第24周时24小时咳嗽频率的影响以及确定截至第24周时BLU-5937与安慰剂相比在RCC（包括不明原因的慢性咳嗽）成人患者中的安全性次要目的：评价BLU-5937对咳嗽频率和PRO等其他指标的影响探索性目的：评价BLU-5937对咳嗽频率和PRO等其他指标的影响

开始日期2024-06-21

申办/合作机构

Patheon, Inc.

[+3]

NCT06222892

/ Completed临床1期

A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Safety of Camlipixant in Male and Female Participants Aged 18-75 Years of Age With Hepatic Impairment Compared to Matched Healthy Participants With Normal Hepatic Function

The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.

开始日期2024-02-02

申办/合作机构

BELLUS Health, Inc.

100 项与 Camlipixant 相关的临床结果

登录后查看更多信息

100 项与 Camlipixant 相关的转化医学

登录后查看更多信息

100 项与 Camlipixant 相关的专利（医药）

登录后查看更多信息

14

项与 Camlipixant 相关的文献（医药）

2025-08-01·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Initial Success: Camlipixant in Refractory Chronic Cough

Letter

作者: Chen, Zhe ; Rui, Yang

2025-08-01·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Reply to Rui and Chen: Initial Success: Camlipixant in Refractory Chronic Cough

Letter

作者: Smith, Jaclyn A.

2025-06-01·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE)

Article

作者: Shaw, Joan ; McGarvey, Lorcan ; Garin, Margaret ; Lanouette, Sylvain ; Birring, Surinder S. ; Yang, Ronghua ; Morice, Alyn H. ; Smith, Jaclyn A. ; Carroll, Kevin J. ; Blaiss, Michael S. ; Bonuccelli, Catherine M. ; Sher, Mandel

Rationale: There is no broadly accessible treatment for patients with refractory chronic cough, a disease characterized by chronic cough that persists despite treatment for other cough-related etiologies or has no identified underlying cause. Objectives: SOOTHE (NCT04678206), a phase 2b, randomized, placebo-controlled trial, evaluated the efficacy and safety of P2X3 antagonist camlipixant in adults with refractory chronic cough (cough duration, ⩾1 yr; baseline awake cough frequency, ⩾25 coughs/h). Methods: After a single-blind, 16-day placebo run-in, patients were randomized (1:1:1:1) to receive camlipixant 12.5, 50, or 200 mg twice daily or placebo for 4 weeks. The primary endpoint was change from baseline to Day 28 in objective 24-hour cough frequency. Secondary endpoints included cough severity and cough-related quality of life. Measurements and Main Results: Overall, 310 patients were randomized. A statistically significant reduction in placebo-adjusted 24-hour cough frequency was seen in the 50 mg (-34.4%; 95% confidence interval, -50.5 to -13.3; P = 0.0033) and 200 mg (-34.2%; 95% confidence interval, -50.7 to -12.2; P = 0.0047) camlipixant arms. All camlipixant arms showed a trend for greater improvement in cough severity visual analog scale and Leicester Cough Questionnaire scores over placebo. Camlipixant was well tolerated with no serious treatment-emergent adverse events reported. Taste alteration occurred in 4.8-6.5% of patients in camlipixant arms (vs. 0% with placebo); these were usually mild-moderate. Conclusions: Camlipixant treatment reduced cough frequency and improved patient-reported outcomes in patients with refractory chronic cough, with an acceptable safety profile. Clinical trial registered with www.clinicaltrials.gov (NCT04678206).

105

项与 Camlipixant 相关的新闻（医药）

2025-10-25

·医药地理

一周药讯：国家药监局关于发布仿制药参比制剂目录（第九十七批）的通告

扫描关注医药地理数据库后台回复第43期即可下载目录行业政策 1.国家药监局：2025医疗器械经济信息发布会在合肥召开 2.国家药监局：关于发布仿制药参比制剂目录（第九十七批）的通告（2025年第37号） 3.广东省药品交易中心：关于公示广东联盟常见病慢性病药品接续采购调平拟中选结果的通知 4.广州市卫健委：关于印发进一步推动创新药械应用十二条措施的通知 5.广西壮族自治区医保局：关于做好二十六省联盟药品集中带量采购中选结果落地实施相关工作的通知 6.上海阳光医药采购网：关于公布第十一批国家组织药品集中采购企业相关信息的通知行业动态 1. 药讯动态：重磅获批 2. 药讯动态：重磅临床 3. 药企动态：市场动态零售行业动态开药店暂停受理零售药店申请医保本周总结政策解读 1、国家药监局：2025医疗器械经济信息发布会在合肥召开 10月21日，由国家药监局南方医药经济研究所主办的“2025医疗器械经济信息发布会”在合肥召开。会议指出，全国药监部门认真贯彻落实习近平总书记“四个最严”要求，持续深化审评审批制度改革，持续强化全生命周期质量安全监管，持续促进全球监管趋同协调信赖，医疗器械高质量发展和高水平安全不断向前推进。国家药监局将进一步完善法律标准体系，加大研发创新支持力度，提高审评审批质效，全方位筑牢医疗器械高水平安全底线，加快创新产品上市步伐，促进医疗器械产业创新高质量发展。具体信息请登录国家药监局官网查看。 2、国家药监局：关于发布仿制药参比制剂目录（第九十七批）的通告（2025年第37号）经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第九十七批）。特此通告。附件：化学仿制药参比制剂目录（第九十七批）.doc 相关文件请扫描上方二维码查看 3、广东省药品交易中心：关于公示广东联盟常见病慢性病药品接续采购调平拟中选结果的通知按照《广东省药品交易中心关于开展广东联盟常见病慢性病药品接续采购未过评申报品规调平确认工作的通知》有关要求，相关企业在规定时间内进行了调平价格确认工作。根据《广东联盟常见病慢性病药品接续采购文件（GDYJYPDL202502）》有关规定和工作安排，现将广东联盟常见病慢性病药品接续采购调平拟中选结果予以公示（详见附件），公示时间为2025年10月22日至2025年10月24日17:30。具体信息请登录广东省药品交易中心官网查看。附件：广东联盟常见病慢性病药品接续采购调平拟中选结果公示表.xlsx 相关文件请扫描上方二维码查看 4、广州市卫健委：关于印发进一步推动创新药械应用十二条措施的通知 10月20日，广州市卫健委发出《关于印发进一步推动创新药械应用十二条措施的通知》，提出了畅通创新药械入院全流程、优化创新药械发展生态等12条具体措施。具体信息请登录广州市卫健委官网查看。 5、广西壮族自治区医保局：关于做好二十六省联盟药品集中带量采购中选结果落地实施相关工作的通知为做好新疆二十六省联盟药品集中带量采购中选结果在我区落地执行，现就有关事项通知。具体信息请登录广西壮族自治区医保局官网查看。附件：二十六省联盟药品集中带量采购中选品种供应清单.xlsx 相关文件请扫描上方二维码查看 6、上海阳光医药采购网：关于公布第十一批国家组织药品集中采购企业相关信息的通知现公布已通过第十一批国家组织药品集中采购信息审核的企业相关信息，包括每品种各厂牌的医药机构报量、同品种有报量的各厂牌平均值、企业GMP符合性检查相关证明材料和企业间关系情况（详见附件）。特此通知。附件：第十一批国家组织药品集中采购企业相关信息表.pdf 相关文件请扫描上方二维码查看行业动态 01 药讯动态：重磅获批最近重磅获批 NMPA批准那米司特片上市：用于治疗成人特发性肺纤维化（IPF）。 FDA批准奥妥珠单抗新适应症上市：用于治疗正在接受标准治疗的活动性狼疮性肾炎（LN）成人患者。 FDA批准口服司美格鲁肽片新适应症上市：用于降低高风险 2 型糖尿病成人患者的主要不良心血管事件（MACE）风险，包括既往无心血管事件的一级预防人群和有心血管病史的二级预防人群。 NMPA批准注射用博度曲妥珠单抗上市：用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。 FDA授予SGB-9768注射液孤儿药资格：用于治疗C3肾小球病（C3 glomerulopathy，C3G）。 CDE将注射用JSKN003纳入突破性疗法认定名单：单药用于治疗既往经奥沙利铂、氟尿嘧啶和伊立替康治疗失败的HER2阳性晚期结直肠癌。 02 药讯动态：重磅临床最近重磅临床 NMPA批准注射用BL-M24D1（ADC）开展临床试验：用于治疗复发或难治性血液系统恶性肿瘤和晚期实体瘤。 CDE批准SA1211注射液开展临床试验：用于用于治疗慢性乙型肝炎。 CDE批准EGFNASA胶囊开展临床试验：用于治疗子宫内膜异位症。 CDE批准BLU-5937片开展临床试验：用于治疗难治性慢性咳嗽。诺华宣布，司库奇尤单抗在III期REPLENISH研究中达到了主要终点及所有次要终点。在风湿性多肌痛（PMR）成人患者中，截至第52周，司库奇尤单抗相较于安慰剂展现出具有统计学显著性和临床意义的持续缓解。 03 药企动态：市场动态 10月21日，Hologic, Inc. (Nasdaq: HOLX，中文名豪洛捷)宣布已签订最终协议，将由Blackstone（黑石资本）和TPG管理的基金以每股79美元的价格收购，企业价值高达183亿美元。根据协议条款，Blackstone和TPG将以每股76美元的现金加上不可交易的或有价值权（CVR）收购所有已发行的Hologic股份，分两次支付，每次最高1.5美元，总对价最高为每股79美元的现金。 10月22日，信达生物宣布与武田制药（Takeda）达成全球战略合作，共同加速推进信达生物新一代肿瘤免疫（IO）与抗体偶联药物（ADC）疗法的全球开发，打造创新癌症治疗方案，造福全球患者。武田制药将向信达生物支付12亿美元首付款，其中包括1亿美元的战略股权投资。此外，信达生物还有权获得IBI363、IBI343及IBI3001（若武田行使选择权）的研发与销售里程碑付款，总计约102亿美元，本次合作交易总金额最高可达114亿美元。 10月22日，Alkermes plc（NASDAQ：ALKS）和Avadel Pharmaceuticals plc（NASDAQ：AVDL）宣布两家公司已达成最终协议。计划中的收购将Avadel的FDA批准产品LUMRYZ™（羟丁酸钠口服混悬液）添加到Alkermes的商业产品组合中，用于治疗7岁以上发作性睡病患者的猝倒或白天过度嗜睡。这一战略举措加快了Alkermes进入睡眠药物市场的步伐。零售行业动态 01 开药店暂停受理零售药店申请医保近日，安徽宿州市医保局发布《关于暂停受理零售药店申请定点协议管理的通告》，以合理配置区域医药资源，科学优化定点零售药店整体布局，提高定点零售药店协议管理服务水平，进一步保障参保人员的购药服务需求。该公告提到，自2025年11月1日起，各级医保经办机构暂停受理零售药店申请医保定点协议管理业务。待我市医保定点零售药店资源规划出台后，将依据相关规定另行通告。在2025年11月1日前正式提交完整申请材料的零售药店，医保经办机构按原办法和流程进行受理、审核及评估。具体信息请登录安徽省宿州市医保局官网查看。本周总结行业政策国家药监局深化医疗器械审评审批制度改革，强化质量安全监管，促进产业创新；国家药监局发布仿制药参比制剂目录（第九十七批），推动一致性评价工作，强化仿制药质量与疗效监管；广东省药品交易中心公示广东联盟慢性病药品调平拟中选结果；广州市卫健委推动创新药械应用的12条措施；广西壮族自治区医保局落实新疆二十六省联盟药品集中带量采购等。行业动态多款新研发的药品或新适应症获得上市许可，同时还有多款药物正在开展临床试验。那米司特片、奥妥珠单抗、司美格鲁肽片、注射用博度曲妥珠单抗等药物获批上市，用于治疗成人特发性肺纤维化（IPF）、活动性狼疮性肾炎（LN）成人患者、HER2阳性乳腺癌患者等。同时注射用BL-M24D1、SA1211注射液、EGFNAS胶囊等新药获批临床试验，用于治疗复发或难治性血液系统恶性肿瘤和晚期实体瘤、慢性乙型肝炎、子宫内膜异位症等；Hologic 被 Blackstone 和 TPG 收购，估值 183 亿美元；信达生物与武田制药达成合作，交易总额最高 114 亿美元；Alkermes 收购 Avadel Pharmaceuticals，整合其产品 LUMRYZ™，加速进入睡眠药物市场。零售动态为优化医药资源配置、提升定点零售药店管理水平及保障参保人员购药需求，安徽省宿州市现暂停受理零售药店医保定点协议管理申请。来源：由中国医药工业信息中心整理 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

带量采购一致性评价申请上市引进/卖出

2025-03-10

·Endpoints

Trevi’s mid-stage chronic cough data meet ‘home run’ scenario, stock soars

Trevi Therapeutics’ chronic cough drug reduced patients’ 24-hour cough frequency by 57% compared to placebo in a Phase 2a trial, exceeding investors’ expectations. The company’s stock $TRVI soared 40% at market open as a result. Leerink analysts said the data hit a “home run scenario,” noting that the candidate, named Haduvio, showed similar efficacy in patients with both moderate and severe cough at baseline. In the RIVER study, patients with severe cough at baseline saw a 66% reduction in 24-hour cough frequency after taking the treatment, while those in the moderate cough group had a 68% reduction (both with a p-value of less than 0.0001). Haduvio is an oral extended-release version of an old pain medicine called nalbuphine. According to Trevi, the drug works on opioid receptors that play a role in controlling cough hypersensitivity. Nalbuphine is not currently considered a controlled substance , which refers to a drug or substance regulated by the government because of its potential for abuse or addiction. A Trevi spokesperson told Endpoints News that the company doesn’t expect Haduvio to be scheduled as a controlled substance. In its news release, the company said that there were no treatment-emergent serious adverse events. The company plans on discussing its next steps with the FDA and expects to initiate the next study with the agency’s input. “The competitive landscape in the last couple of years has thinned out due to multiple failures,” Trevi’s CEO Jennifer Good said on a Monday morning call with investors. “With the strength of the RIVER data and the sparse competitive landscape, we believe Haduvio has the potential to be best-in-class in patients with RCC.” RCC refers to refractory chronic cough, or a persistent cough lasting more than eight weeks that isn’t resolved by standard treatments. There are currently no approved treatments for RCC. Trevi’s main competitor in RCC is GSK’s Phase 3 candidate camlipixant, which was a focal point of its $2 billion Bellus acquisition in 2023. The company is set to read out late-stage results in the second half of this year. While it is nearly impossible to compare data across trials, recently published Phase 2b camlipixant results showed a placebo-adjusted reduction in 24-hour cough rate of 34% in patients who experienced 25 or more coughs per hour at baseline. Trevi classified severe cough as patients who experience 20 or more coughs per hour. Trevi made clear that idiopathic pulmonary fibrosis, a chronic lung disease, is still its priority for Haduvio. The company expects to have Phase 2b results in IPF patients with chronic cough in the second quarter.

临床2期临床结果临床3期并购

2025-03-10

·Firstwordpharma

Trevi soars on hopes for refractory chronic cough treatment

With no FDA-approved treatments for refractory chronic cough (RCC), patients have long faced limited options – but Trevi Therapeutics is hoping to change that. On Monday, the company announced that its investigational oral therapy Haduvio (nalbuphine extended-release) met its primary endpoint in the Phase IIa RIVER trial, showing a statistically significant 57% placebo-adjusted reduction in 24-hour cough frequency.The crossover study, which enrolled 66 patients with RCC, demonstrated that Haduvio reduced cough frequency by 67% from baseline, compared to 10% with placebo. The therapy also showed similar efficacy in both moderate (10-19 coughs/hour) and severe (20+ coughs/hour) patient subgroups, with reductions of 68% and 66%, respectively.Trevi plans to discuss next steps with the FDA while continuing its parallel Phase IIb CORAL trial in chronic cough associated with idiopathic pulmonary fibrosis (IPF), which recently completed enrollment. Topline results there are due this half."The RIVER trial demonstrated that Haduvio was highly effective, and worked quickly at the lowest dose tested across a broad range of cough counts," said CEO Jennifer Good. "These results, coupled with our existing IPF chronic cough results, are further evidence of the effectiveness of Haduvio's central and peripheral KAMA mechanism in treating these difficult neurological cough conditions." Company shares were up over 41% on the news Monday.While Trevi's success may be capturing investor attention, other players have struggled to gain traction in the space. In 2023, Merck & Co. received a second complete response letter from the FDA for its oral P2X3 receptor antagonist gefapixant, despite the drug being approved in Europe and Japan. The US regulator had concluded that Merck's application "did not meet substantial evidence of effectiveness" for treating refractory or unexplained chronic cough.Meanwhile, GSK is hoping camlipixant, another P2X3 antagonist, can help turn the company's fortunes around (see – Vital Signs: Pharma's worst performers of 2024, and how they can turn the tide in 2025). Phase III results for the drug, which GSK acquired through its $2-billion deal for Bellus Health, are expected at the end of this year.In Phase IIb SOOTHE trial results published earlier this month in the American Journal of Respiratory and Critical Care Medicine, camlipixant demonstrated a 34% placebo-adjusted reduction in 24-hour cough frequency.Before the RIVER readout, Oppenheimer analysts said they "lean optimistic that Haduvio's performance in RIVER will open the door to a sizable second opportunity in RCC patients inadequately addressed by other therapies." Specifically, they highlighted that efficacy in the severe cough segment would "best inform its prospects for those in whom alternatives, including GSK's Phase III-stage camlipixant, are insufficient."

临床2期临床结果临床3期

100 项与 Camlipixant 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不明原因的慢性咳嗽	临床3期	日本	BELLUS Health Cough, Inc.	2022-12-05
不明原因的慢性咳嗽	临床3期	澳大利亚	BELLUS Health Cough, Inc.	2022-12-05
不明原因的慢性咳嗽	临床3期	捷克	BELLUS Health Cough, Inc.	2022-12-05
不明原因的慢性咳嗽	临床3期	印度	BELLUS Health Cough, Inc.	2022-12-05
难治性慢性咳嗽	临床3期	美国	BELLUS Health, Inc.	2022-10-25
难治性慢性咳嗽	临床3期	阿根廷	BELLUS Health, Inc.	2022-10-25
难治性慢性咳嗽	临床3期	比利时	BELLUS Health, Inc.	2022-10-25
难治性慢性咳嗽	临床3期	加拿大	BELLUS Health, Inc.	2022-10-25
难治性慢性咳嗽	临床3期	哥伦比亚	BELLUS Health, Inc.	2022-10-25
难治性慢性咳嗽	临床3期	法国	BELLUS Health, Inc.	2022-10-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04678206 (SOOTHE, Pubmed \| Am J Respir Crit Care Med)	临床2期	难治性慢性咳嗽	310	Camlipixant 50 mg	衊餘積積鹽獵淵齋鹹築(餘膚範糧構餘鹽廠範鑰) = 壓膚範繭襯壓簾鹹窪艱鏇膚鑰壓構鬱襯獵夢夢 (糧醖鏇衊觸選願鏇觸糧, -50.5 ~ -13.3)	积极	2025-06-01
				Camlipixant 200 mg	衊餘積積鹽獵淵齋鹹築(餘膚範糧構餘鹽廠範鑰) = 範鏇獵觸積觸醖壓鑰艱鏇膚鑰壓構鬱襯獵夢夢 (糧醖鏇衊觸選願鏇觸糧, -50.7 ~ -12.2)
ATS2025	临床1期	-	38	Camlipixant 50 mg	鏇蓋簾構積鹹醖壓遞構(糧範網構鑰顧壓鬱築獵) = a dose-dependent QT prolongation was observed in by-time point analysis after dosing at 200 and 400 mg 鬱顧鹽鏇簾遞繭廠窪選 (淵衊壓淵繭齋積鏇膚衊 ) 更多	积极	2025-05-16
				Camlipixant 200 mg
NCT05959447 (CTgov)	临床1期	咳嗽	45	Gemfibrozil+Camlipixant (Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg)	積憲夢鹹遞鬱積夢築觸(襯壓簾淵廠鏇網夢獵醖) = 觸遞顧鏇築齋襯齋齋繭衊選觸鬱醖糧鹹衊築廠 (憲鹽襯糧鬱鹹壓鏇鏇繭, 28.69) 更多	-	2025-03-26
				Dabigatran etexilate+Camlipixant (Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg)	壓網遞醖鹽繭鹹繭築糧(觸鏇餘遞鑰衊膚窪選鑰) = 餘選壓淵襯構獵醖鏇顧壓簾襯積製膚範製壓簾 (築艱鑰鏇積夢淵鑰製鹽, 52.12) 更多
NCT05899829 (CTgov)	临床1期	咳嗽	42	Rifampin+Camlipixant (Part 1: Camlipixant 50 mg + Rifampin 600 mg)	淵顧鑰憲鬱遞鬱膚壓鬱(製壓網鹹夢鹽選選願願) = 糧選衊鹹觸製繭網網糧餘窪鹹膚築構餘積廠廠 (鑰壓艱衊餘獵餘醖鏇鏇, 39.27) 更多	-	2024-12-04
				Rabeprazole+Camlipixant (Part 2: Camlipixant 50 mg + Rabeprazole 20 mg)	觸鹽鑰鏇築壓窪築遞網(鹽選鹹鹽襯艱糧鹹構夢) = 蓋觸糧鹹顧鹽蓋積範選積憲觸鹹鹽網醖衊窪淵 (築鹹蓋願鹽壓鹽鏇觸淵, 29.55) 更多
NCT04678206 (SOOTHE, ERS2022)	临床2期	难治性慢性咳嗽	-	BLU-5937 12.5 mg BID	餘觸遞醖夢網廠襯壓醖(廠顧壓衊網蓋獵淵鏇淵) = 廠觸鏇製鹹鏇積願範構齋鑰憲觸憲蓋蓋獵顧觸 (壓鑰獵醖鹽製構壓糧獵 ) 更多	积极	2022-09-04
				BLU-5937 50 mg BID	餘觸遞醖夢網廠襯壓醖(廠顧壓衊網蓋獵淵鏇淵) = 蓋餘選艱鬱鏇齋積窪醖齋鑰憲觸憲蓋蓋獵顧觸 (壓鑰獵醖鹽製構壓糧獵 ) 更多
NCT04678206 (SOOTHE, ERS2022)	临床2期	难治性慢性咳嗽 P2X3	-	BLU-5937 12.5 mg BID	憲鏇鹽構壓齋選艱製醖(繭餘網選遞獵齋壓艱糧) = Treatment-emergent TDAEs were reported by 4.8, 6.5, 4.8 and 0% of participants in the 12.5, 50, 200 mg BID and placebo groups, respectively. Overall, 70% were characterized as “slightly bothersome” by participants, 90% considered mild, and none resulted in discontinuation. 鬱鬱獵選構糧廠獵鏇鹽 (鹽範鬱衊願範鬱艱願願 )	积极	2022-09-04
				BLU-5937 50 mg BID
ATS2022	N/A	难治性慢性咳嗽	-	BLU-5937 12.5 mg BID	醖鑰顧構艱憲網糧壓艱(鏇糧蓋廠餘膚觸鏇鏇淵) = 鏇簾構糧願積廠網繭鏇壓艱窪遞鹽醖糧廠簾憲 (窪選夢簾襯觸淵願鑰糧 ) 更多	-	2022-05-15
				BLU-5937 50 mg BID	醖鑰顧構艱憲網糧壓艱(鏇糧蓋廠餘膚觸鏇鏇淵) = 壓網淵膚選廠範築選獵壓艱窪遞鹽醖糧廠簾憲 (窪選夢簾襯觸淵願鑰糧 ) 更多
NCT04678206 (SOOTHE, Corporate Publications) 人工标引	临床2期	难治性慢性咳嗽	300	Camlipixant	衊蓋壓繭繭顧衊壓糧鑰(鹹鹹鹽選繭選廠網襯築) = At least one dose of BLU-5937 met the stringent predefined probability threshold for a clinically meaningful reduction in placebo-adjusted 24-hour cough frequency; 膚築襯構範顧網醖顧齋 (積網壓網醖艱窪簾構鹽 ) 更多	积极	2021-09-13
				Placebo
NCT03979638 (RELIEF, CTgov)	临床2期	难治性慢性咳嗽	68	BLU-5937 (BLU-5937 - 25 mg)	齋廠廠齋廠淵壓淵鏇觸(艱齋壓窪網夢願繭構鏇) = 鹹網糧積範膚鬱繭襯艱鹹蓋淵築顧膚網簾遞襯 (鹹鹽築窪窪醖憲餘鬱鬱, 築製構構鹹繭鏇鬱齋衊 ~ 蓋觸廠顧顧襯遞範襯淵) 更多	-	2021-08-03
				Placebo (Placebo Comparator - 25 mg)	齋廠廠齋廠淵壓淵鏇觸(艱齋壓窪網夢願繭構鏇) = 鹽膚廠積獵顧願餘淵顧鹹蓋淵築顧膚網簾遞襯 (鹹鹽築窪窪醖憲餘鬱鬱, 鬱鬱淵窪衊齋構淵網遞 ~ 構鹽齋築願醖鏇壓窪獵) 更多
ATS2021	N/A	咳嗽	-	BLU-5937 25 mg bid	餘壓糧鑰鑰糧願鹹鬱壓(鹽鑰鹽願鹹鬱製構網觸) = 衊網餘製獵製窪遞獵範觸襯鏇願壓襯憲夢壓顧 (網壓鹹醖鏇鏇蓋鑰觸選 ) 更多	-	2021-05-03
				BLU-5937 50 mg bid	餘壓糧鑰鑰糧願鹹鬱壓(鹽鑰鹽願鹹鬱製構網觸) = 繭餘衊簾憲遞艱淵鏇襯觸襯鏇願壓襯憲夢壓顧 (網壓鹹醖鏇鏇蓋鑰觸選 ) 更多